Phaseline

Companies › Shanghai Henlius Biotech

Shanghai Henlius Biotech: clinical trials, targets and expected readouts

20 active drug programs in 146 registered trials: 105 Phase 2, 21 Phase 1, 18 Phase 3, 2 Phase 4; Oncology, Genitourinary, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Serplulimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Extensive Stage Small Cell Lung Cancer; Limited-Stage Small Cell Lung Cancer; Non Small Cell Lung Cancer; Metastatic Colorectal Cancer …Nov 2026
HLX22
HER2-targeted monoclonal antibody
ERBB2Phase 3Gastroesophageal-junction Cancer; HER2-low Hormone Receptor Positive Breast Cancer; HER2 + Breast CancerJun 2027
Pertuzumab (HLX11)
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Breast Cancer; Elderly Females; Metastatic Breast Cancer; Invasive Breast Cancer …–
HLX43
anti-PD-L1 antibody-drug conjugate with topoisomerase I inhibitor payload
CD274Phase 2Nasopharyngeal Carcinoma (NPC); Non Small Cell Lung Cancer; Colorectal Cancer (CRC); Cervical Cancer …Nov 2026
Bevacizumab (HLX04)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Metastatic Colorectal Cancer; Carcinoma, HepatocellularDec 2026
HLX79
Human sialidase fusion protein
–Phase 2Membranous NephropathyJan 2027
Rituximab (HLX01)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 2Membranous NephropathyJan 2027
HLX53
Anti-TIGIT Fc fusion protein
TIGITPhase 2Carcinoma, HepatocellularFeb 2027
HLX26
Anti-LAG-3 monoclonal antibody
LAG3Phase 2NSCLC Stage IVJul 2027
Pimurutamab (HLX07)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Carcinoma of Head and/or Neck; Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Rectal CancerDec 2027
HLX13
CTLA-4 inhibitor (anti-CTLA-4 monoclonal antibody biosimilar)
CTLA4Phase 1Hepatocellular Carcinoma (HCC)Dec 2026
HLX05
anti-EGFR monoclonal antibody
EGFRPhase 1Cancer; EGFR OverexpressionDec 2026
HLX48
EGFR/c-MET bispecific antibody-drug conjugate
EGFR, METPhase 1Advanced/Metastatic Solid TumorsMar 2027
Pembrolizumab (HLX17)
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Non-small Cell Lung CancerApr 2027
HLX15-SC
anti-CD38 monoclonal antibody
SDCL2Phase 1Multiple Myeloma (MM)May 2027
Cetuximab (HLX42)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Solid Tumor and NSCLCJun 2027
HLX3902–Phase 1mCRPC or Advanced/Metastatic Solid TumorsJun 2027
HLX18
PD-1 inhibitor
PDCD1Phase 1Esophageal and/or Cardia CancerAug 2027
HLX316–Phase 1Advanced/Metastatic Solid TumorsDec 2027
HLX3901–Phase 1SCLCMay 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03161353Pertuzumab (HLX11)Phase 2Breast CancerOncologyNov 2023
NCT05346224Pertuzumab (HLX11)Phase 3Breast CancerOncologyMay 2024
NCT02625441Pertuzumab (HLX11)Phase 3Breast CancerOncologyJun 2025
NCT04680442Pertuzumab (HLX11)Phase 2Breast CancerOncologyDec 2025
NCT06980454HLX05Phase 1CancerOncologyDec 2025
NCT06368141SerplulimabPhase 2Colon CancerOncologyFeb 2026
NCT05585580SerplulimabPhase 2Advanced Gastric or Gastroesophageal Junction AdenocarcinomaOncologyApr 2026
NCT06911606SerplulimabPhase 2SCLC, Limited StageOncologyJun 2026
NCT06576921SerplulimabPhase 2Stomach NeoplasmsOncologyAug 2026
NCT06839066HLX43Phase 2Nasopharyngeal Carcinoma (NPC)OncologyNov 2026
NCT07269782HLX43Phase 2Non Small Cell Lung CancerOncologyNov 2026
NCT07269782SerplulimabPhase 2Non Small Cell Lung CancerOncologyNov 2026
NCT07108127Pertuzumab (HLX11)Phase 2Rectal CancerOncologyDec 2026
NCT03595592Pertuzumab (HLX11)Phase 3Invasive Breast CancerOncologyDec 2026
NCT05891561Pertuzumab (HLX11)Phase 2Breast CancerOncologyDec 2026
NCT06542588SerplulimabPhase 2Rectal CancerOncologyDec 2026
NCT07283692SerplulimabPhase 2Triple Negative Breast CancerOncologyDec 2026
NCT06497530SerplulimabPhase 2Extensive-Stage Small Cell Lung CancerOncologyDec 2026
NCT06542588Pimurutamab (HLX07)Phase 2Rectal CancerOncologyDec 2026
NCT07176650HLX13Phase 1Hepatocellular Carcinoma (HCC)OncologyDec 2026
NCT05954429SerplulimabPhase 2Colorectal CancerOncologyDec 2026
NCT07106892HLX43Phase 2Colorectal Cancer (CRC)OncologyDec 2026
NCT04547166SerplulimabPhase 2Metastatic Colorectal CancerOncologyDec 2026
NCT05837052SerplulimabPhase 2Unresectable Lung Non-Small Cell CarcinomaOncologyDec 2026
NCT05731726SerplulimabPhase 2pMMROncologyDec 2026
NCT04547166Bevacizumab (HLX04)Phase 2Metastatic Colorectal CancerOncologyDec 2026
NCT06769152HLX43Phase 2Cervical CancerOncologyDec 2026
NCT04750122Pertuzumab (HLX11)Phase 1HER2-positive Early Breast CancerOncologyDec 2026
NCT06727617SerplulimabPhase 2Cervical CancersOncologyDec 2026
NCT05765825SerplulimabPhase 2Extensive-stage Small-cell Lung CancerOncologyDec 2026
NCT06280495SerplulimabPhase 2Colorectal CancerOncologyDec 2026
NCT06433869SerplulimabPhase 2Malignant AscitesOncologyDec 2026
NCT05957510SerplulimabPhase 2Small-cell Lung CancerOncologyDec 2026
NCT06309043HLX05Phase 1EGFR OverexpressionOtherDec 2026
NCT06136897Pertuzumab (HLX11)Phase 2Malignant Solid NeoplasmOncologyJan 2027
NCT07038382HLX79Phase 2Membranous NephropathyGenitourinaryJan 2027
NCT07038382Rituximab (HLX01)Phase 2Membranous NephropathyGenitourinaryJan 2027
NCT06295926SerplulimabPhase 2Small Cell Lung CancerOncologyJan 2027
NCT07257575SerplulimabPhase 2Gastric Cancer Stage IIIOncologyJan 2027
NCT06349980SerplulimabPhase 2Carcinoma, HepatocellularOncologyFeb 2027
NCT06349980Bevacizumab (HLX04)Phase 2Carcinoma, HepatocellularOncologyFeb 2027
NCT06349980HLX53Phase 2Carcinoma, HepatocellularOncologyFeb 2027
NCT07277439SerplulimabPhase 2Gastric CancerOncologyFeb 2027
NCT07473726HLX48Phase 1Advanced/Metastatic Solid TumorsOncologyMar 2027
NCT06601309SerplulimabPhase 2Esophageal Squamous Cell CarcinomaOncologyMar 2027
NCT05766800SerplulimabPhase 2Locally AdvancedOncologyApr 2027
NCT04588545Pertuzumab (HLX11)Phase 1HER2-positive Breast CancerOncologyApr 2027
NCT07101679SerplulimabPhase 2Locally Advanced Pancreatic Ductal AdenocarcinomaOncologyApr 2027
NCT07160335Pembrolizumab (HLX17)Phase 1Non-small Cell Lung CancerOncologyApr 2027
NCT07583511SerplulimabPhase 2Small-cell Lung CancerOncologyMay 2027
NCT07477587HLX15-SCPhase 1Multiple Myeloma (MM)OncologyMay 2027
NCT07596121SerplulimabPhase 2NSCLC (Non-small Cell Lung Cancer)OncologyMay 2027
NCT06532006HLX22Phase 3Gastroesophageal-junction CancerOncologyJun 2027
NCT06832202HLX22Phase 2HER2-low Hormone Receptor Positive Breast CancerOncologyJun 2027
NCT06742892HLX43Phase 2Carcinoma, HepatocellularOncologyJun 2027
NCT06769113HLX43Phase 2Esophageal CancerOncologyJun 2027
NCT06210815Cetuximab (HLX42)Phase 1Solid Tumor and NSCLCOncologyJun 2027
NCT07253142SerplulimabPhase 2Non Small Cell Lung CancerOncologyJun 2027
NCT07253142SerplulimabPhase 2Non Small Cell Lung CancerOncologyJun 2027
NCT07533708HLX3902Phase 1mCRPC or Advanced/Metastatic Solid TumorsOncologyJun 2027

The 60 nearest readouts of 146 trials; the rest in the app.

Targets

EGFR (4) PDCD1 (3) ERBB2 (2) CD274 (1) MET (1) VEGFA (1) TIGIT (1) MS4A1 (1) CTLA4 (1) LAG3 (1) SDCL2 (1)

Companies with the same targets

AstraZeneca Roche Beijing Biotech Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Pfizer Akeso Shenyang Sunshine Pharmaceutical Johnson & Johnson (Janssen) Sichuan Baili Pharmaceutical

Companies built like this

Sichuan Baili Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shenyang Sunshine Pharmaceutical Akeso Merck KGaA

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.